RESUMEN
OBJECTIVE: Evaluation of the first excimer laser treatments of myopia. DESIGN: Descriptive. SETTING: Excimer Laser Centrum, Department of Ophthalmology, University of Nijmegen, Nijmegen, the Netherlands. METHOD: 312 patients underwent spherical excimer laser treatment to correct myopia of 1.2 up to 10 diopters between February 1992 and October 1993. 245 patients completed a follow-up of one year or more; 36 retreatments were carried out. Group I (treatment 1.2 to 6 D) numbered 174 patients, group II (6.1-10 D) 71 patients. RESULTS: After a follow-up period of one year or just before retreatment 79% of group I and 48% of group II achieved a refractive correction within 1 D of the attempted correction. Visual acuity without correction was 0.5 or more in 94% of group I and in 76% of group II. Less than one percent (n = 1) of group I and 6% (n = 4) of group II lost more than one line of best corrected visual acuity. Retreatment could correct 50% of those eyes that did not achieve a refraction within 1 D of attempted correction. Loss of visual acuity was corrected by retreatment in 5 of 6 cases of group I and in 7 of 11 cases of group II. CONCLUSION: Based on a one-year follow-up, refractive surgery with the excimer laser appears to correct myopia between 1 and 10 D effectively. Predictability is diminishing on correcting higher amounts of refractive error. Thorough information of the patients regarding the results to be expected will prevent disappointment.
Asunto(s)
Miopía/cirugía , Queratectomía Fotorrefractiva/métodos , Adolescente , Adulto , Femenino , Humanos , Láseres de Excímeros , Masculino , Persona de Mediana Edad , Miopía/fisiopatología , Refracción Ocular , Reoperación , Agudeza VisualRESUMEN
Bromovinyldeoxyuridine is a potent and safe antiherpes compound that in combination with a placebo treatment promoted the partial and complete healing of herpetic epithelial disease in 22 patients in average times of 4-6 days and 8.5 days respectively. However, when BVDU was combined with 1.5 X 10(6) IU of recombinant a 2C interferon, partial and complete healing times for keratitis in 19 patients were reduced to 2-6 days and 4-6 days respectively. No toxic effects of the medications were observed in any patient.
Asunto(s)
Antivirales/uso terapéutico , Bromodesoxiuridina/análogos & derivados , Interferón Tipo I/uso terapéutico , Queratitis Dendrítica/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Bromodesoxiuridina/uso terapéutico , Niño , Ensayos Clínicos como Asunto , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Queratitis Dendrítica/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Proteínas RecombinantesRESUMEN
In a double-masked clinical trial a total of 24 patients have so far been treated with recombinant human alpha 2-interferon in combination with Acyclovir (ACV), and 21 patients with a placebo-Acyclovir combination. Both partial and complete healing times were statistically significantly shortened in the r-Hu IFN-alpha 2-AVC group, by 35 and 32 percent respectively. No difference could be demonstrated between the combination of r-Hu IFN-alpha 2 arg and ACV and that of BCL IFN and ACV as far as the therapeutic effect was concerned. R-Hu IFN-alpha 2 drops in combination with Acyclovir ointment were excellently tolerated.
Asunto(s)
Aciclovir/uso terapéutico , Interferón Tipo I , Interferón gamma/administración & dosificación , Queratitis Dendrítica/tratamiento farmacológico , Aciclovir/administración & dosificación , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Interferón-alfa , Masculino , Persona de Mediana Edad , Pomadas , Soluciones Oftálmicas , Distribución Aleatoria , Proteínas Recombinantes/administración & dosificaciónRESUMEN
No statistical difference was found in both partial and complete healing time in acute epithelial herpetic keratitis between the ACV-recombinant human alpha 2 IFN (both "eyedrops" and "eyerods") and Buffy coat human leucocyte alpha IFN. A highly significant difference was found in both partial and complete healing time between the ACV-IFN combination versus the ACV-Placebo combination. The combination of ACV and recombinant human alpha 2 arg IFN is a potent anti-herpetic treatment.
Asunto(s)
Aciclovir/uso terapéutico , Interferón Tipo I/uso terapéutico , Queratitis Dendrítica/terapia , Ensayos Clínicos como Asunto , ADN Recombinante , Método Doble Ciego , Quimioterapia Combinada , Humanos , Queratitis Dendrítica/tratamiento farmacológico , Proteínas Recombinantes , Factores de TiempoRESUMEN
Nocardia gypsoides, a species characterised by its ability to produce calcium sulphate granules, has been isolated for the first time from a corneal ulcer. In vivo this pseudomycete also forms gypsum. Every effort should be made to identify Actinomycetales to species level. The names Leptothrix and Streptothrix should be abandoned.
Asunto(s)
Úlcera de la Córnea/microbiología , Nocardiosis/microbiología , Nocardia/aislamiento & purificación , Anciano , Cloranfenicol/uso terapéutico , Úlcera de la Córnea/tratamiento farmacológico , Humanos , Masculino , Nocardiosis/tratamiento farmacológicoRESUMEN
An aesthesiometer with disposable monofilaments is designed for measuring very small pressures on the corneal surface. This was achieved by using various lengths of a nylon monofilament with diameters of 0.08, 0.10, and 0.12 mm. With these lengths and diameters pressures between 0.1 and 1.0 g/mm2 can be exerted on the corneal surface.